NASDAQ:ALGS

Aligos Therapeutics Stock Forecast, Price & News

$14.57
-0.10 (-0.68 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.30
$15.22
50-Day Range
$14.57
$33.60
52-Week Range
$12.82
$37.51
Volume87,327 shs
Average Volume339,375 shs
Market Capitalization$555.85 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALGS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aligos Therapeutics logo

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headlines

Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $15.54
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $15.54
July 29, 2021 |  americanbankingnews.com
Aligos Therapeutics (NASDAQ:ALGS) Trading 5% Higher
Aligos Therapeutics (NASDAQ:ALGS) Trading 5% Higher
July 22, 2021 |  americanbankingnews.com
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)
July 18, 2021 |  realmoney.thestreet.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $15.48
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $15.48
July 16, 2021 |  americanbankingnews.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $15.19
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $15.19
July 15, 2021 |  americanbankingnews.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Up 4.6%
Aligos Therapeutics (NASDAQ:ALGS) Shares Up 4.6%
July 14, 2021 |  americanbankingnews.com
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.9%
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.9%
July 13, 2021 |  americanbankingnews.com
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 8.1%
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 8.1%
July 7, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

274th out of 2,223 stocks

Biological Products, Except Diagnostic Industry

36th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aligos Therapeutics (NASDAQ:ALGS) Frequently Asked Questions

Is Aligos Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aligos Therapeutics stock.
View analyst ratings for Aligos Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aligos Therapeutics?

Wall Street analysts have given Aligos Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aligos Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aligos Therapeutics' next earnings date?

Aligos Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Aligos Therapeutics
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings data on Sunday, May, 9th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.90) by $0.16. The business had revenue of $0.91 million for the quarter.
View Aligos Therapeutics' earnings history
.

What price target have analysts set for ALGS?

4 analysts have issued 12-month price objectives for Aligos Therapeutics' shares. Their forecasts range from $28.00 to $42.00. On average, they expect Aligos Therapeutics' share price to reach $34.50 in the next twelve months. This suggests a possible upside of 136.8% from the stock's current price.
View analysts' price targets for Aligos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aligos Therapeutics' key executives?

Aligos Therapeutics' management team includes the following people:
  • Dr. Lawrence M. Blatt, CEO & Chairman (Age 59, Pay $900.08k)
  • Dr. Leonid Beigelman, Pres & Director (Age 62, Pay $690.83k)
  • Dr. Julian A. Symons, Exec. VP & Chief Scientific Officer (Age 60, Pay $580.11k)
  • Ms. Lesley Ann Calhoun, Exec. VP & CFO (Age 55)
  • Ms. Lucinda Y. Quan J.D., Exec. VP, Chief Bus. Officer & Gen. Counsel (Age 48)
  • Mr. John Fry, Exec. VP of Clinical Devel. (Age 58)
  • Dr. Matthew W. McClure M.D., Exec. VP & Chief Medical Officer (Age 50)
  • Mr. Sushmita M. Chanda DABT, Ph.D., Exec. VP of Translational Safety Sciences (Age 55)
  • Dr. David B. Smith Ph.D., Exec. VP & Head of Chemical Operations
  • Dr. Pierre J.M.B. Raboisson Ph.D., Exec. VP, Head of Small Molecule Medicinal Chemistry & Head of Belgium Site (Leuven)

Who are some of Aligos Therapeutics' key competitors?

When did Aligos Therapeutics IPO?

(ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager.

What is Aligos Therapeutics' stock symbol?

Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."

How do I buy shares of Aligos Therapeutics?

Shares of ALGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aligos Therapeutics' stock price today?

One share of ALGS stock can currently be purchased for approximately $14.57.

How much money does Aligos Therapeutics make?

Aligos Therapeutics has a market capitalization of $555.85 million. The company earns $-108,540,000.00 in net income (profit) each year or ($10.87) on an earnings per share basis.

How many employees does Aligos Therapeutics have?

Aligos Therapeutics employs 69 workers across the globe.

What is Aligos Therapeutics' official website?

The official website for Aligos Therapeutics is www.aligos.com.

How can I contact Aligos Therapeutics?

The company can be reached via phone at 800-466-6059 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.